New drugs targeting a specific gene fusion in pediatric leukemia
Novel Small-Molecule Probes Targeting Oncogenic Fusion MLL in Pediatric Leukemia
This study is working on new, safer treatments for kids and teens with a type of leukemia caused by a specific gene change, aiming to make the medicine less harmful than traditional chemotherapy.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Baylor College of Medicine NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-10982502 on NIH RePORTER |
What this research studies
This research focuses on developing small-molecule probes that specifically target the oncogenic fusion of the MLL gene, which is associated with acute leukemia in children and adolescents. The study aims to create less toxic treatment options compared to conventional chemotherapy, which often harms healthy cells and leads to severe side effects. By targeting the unique protein interactions involved in MLL-rearranged leukemia, the researchers hope to improve treatment outcomes and reduce toxicity for affected patients. The project will involve laboratory assays and drug development processes to identify effective inhibitors.
Who could benefit from this research
Good fit: Ideal candidates for this research are children and adolescents diagnosed with acute leukemia, particularly those with MLL-rearranged leukemia.
Not a fit: Patients with other types of leukemia that do not involve MLL gene fusions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to safer and more effective treatments for pediatric leukemia, improving survival rates and quality of life for young patients.
How similar studies have performed: Previous research has shown promise in targeting similar oncogenic fusions, indicating potential for success in this novel approach.
Where this research is happening
Houston, United States
- Baylor College of Medicine — Houston, United States (Active)
Researchers
- Principal investigator: Song, Yongcheng — Baylor College of Medicine
- Study coordinator: Song, Yongcheng
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.